A STUDY OF MABTHERA (RITUXIMAB) IN PARTICIPANTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) AND/OR ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPY.: